Reduction of CD8 T Cell Functionality but Not Inhibitory Capacity by Integrase Inhibitors

• Published in: Journal of virology 2022-03, Vol.96 (5), p.e0173021-e0173021
• Main Authors: Richter, Enrico, Bornemann, Lea, Korencak, Marek, Alter, Galit, Schuster, Marc, Esser, Stefan, Boesecke, Christoph, Rockstroh, Juergen, Gunzer, Matthias, Streeck, Hendrik
• Format: Article
• Language: English
• Subjects: Anti-HIV Agents - pharmacology; Anti-HIV Agents - therapeutic use; CD8-Positive T-Lymphocytes - drug effects; Cellular Response to Infection; HIV Infections - drug therapy; HIV Integrase Inhibitors - pharmacology; Humans; Immunology; Reverse Transcriptase Inhibitors - therapeutic use
• ISSN: 0022-538X; 1098-5514
• DOI: 10.1128/jvi.01730-21

Although HIV-specific CD8 T cells are effective in controlling HIV infection, they fail to clear infection even in the presence of antiretroviral therapy (ART) and cure strategies such as "shock-and-kill." Little is known how ART is contributing to HIV-specific CD8 T cell function and the ability to clear HIV infection. Therefore, we first assessed the cytokine polyfunctionality and proliferation of CD8 T cells from ART-treated HIV+ individuals directly and observed a decline in the multifunctional response as well as proliferation indices of these cells in individuals treated with integrase inhibitor (INSTI) based ART regimens compared to both protease inhibitor (PI) and nonnucleoside reverse transcriptase inhibitor (NNRTI) based regimens. We next cocultured CD8 T cells with different drugs individually and were able to observe reduced functional properties with significantly decreased ability of CD8 T cells to express IFN-γ, MIP1β and TNF-α only after treatment with INSTI-based regimens. Furthermore, previously activated and INSTI-treated CD8 T cells demonstrated reduced capacity to express perforin and granzyme B compared to PI and NNRTI treated cells. Unexpectedly, CD8 T cells treated with dolutegravir showed a similar killing ability 7 dpi compared to emtricitabine or rilpivirine treated cells. We next used a live cell imaging assay to determine the migratory capacity of CD8 T cells. Only INSTI-treated cells showed less migratory activity after SDF-1α stimulation compared to NRTI regimens. Our data show that the choice of ART can have a significant impact on CD8 T cell effector functions, but the importance for potential eradication attempts is unknown. Integrase Strand Transfer Inhibitors (INSTI) are recommended by national and international guidelines as a key component of ART in the treatment of HIV infected patients. In particular, their efficacy, tolerability and low drug-drug interaction profile have made them to the preferred choice as part of the first-line regimen in treatment-naive individuals. Here, we demonstrate that the choice of ART can have a significant impact on function and metabolism of CD8 T cells. In summary, our study provides first evidence on a significant, negative impact on CD8 T cell effector functions in the presence of two INSTIs, dolutegravir and elvitegravir, which may contribute to the limited success of eradicating HIV-infected cells through "shock-and-kill" strategies. Although our findings are coherent with recent s